Pharmaceutical company Evolus has expanded to offer the neurotoxin Nuceiva in Italy.
Nuceiva is approved by the European Commission for the temporary improvement in the appearance of moderate to severe glabellar lines, which Italian patients will now be able to benefit from the treatment.
David Moatazedi, president and CEO of Evolus Inc., said, “We are excited to introduce Nuceiva to medical aesthetic customers in Italy, one of the largest aesthetic toxin markets in Europe and a crucial step in growing our global footprint. Expanding within the dynamic European market continues to be a strategic ambition and will help fuel Evolus’ market growth, globally.”
